Key facts
- Lykos Therapeutics’s last known valuation is $224.0M (Jan 2024).
- It has raised $150.0M; the latest was Later Stage VC ($50.0M) in Aug 2025.
- Notable investors include Impact Assets, True Ventures, KittyHawk, Solari Capital, Lauder Partners — 28 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Lykos Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lykos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lykos Therapeutics
Provider of psychedelic medicines and therapies intended to help people heal and grow. The company specializes in the research, development, and integration of psychedelic medicines and therapies into the healthcare system, applying evidence-based research to create investigational psychedelics to catalyze therapeutic approaches for mental health conditions, enabling adults with post-traumatic stress disorder (PTSD) to address unmet needs in the mental healthcare space.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2014
- Employees
- 89
- Website
- lykospbc.com/
- Ownership
- Privately Held (backing)
Lykos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lykos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lykos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.